6-K - Kazia Therapeutics Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Kazia Therapeutics Limited filed this 6-K to disclose its half-year 2025 financial results, R&D progress, financing, and Nasdaq compliance status.

Key Takeaways

1For the half-year ended 31 December 2025, the Consolidated entity posted a GAAP net loss after tax of $12,552,490, compared to $10,453,811 in the same period of 2024.

2As of 31 December 2025, the Consolidated entity held cash and cash equivalents of $69,459,980, up from $4,344,691 as of 30 June 2025.

3On 18 December 2025, Nasdaq confirmed the company had regained compliance with Listing Rule 5550(b), allowing its ADSs to continue trading on the Nasdaq Capital Market.

4In December 2025, the company completed a PIPE financing raising net proceeds of approximately $46.5 million to support clinical development of lead programs including paxalisib.

5During the half-year, lead asset paxalisib was advanced into multiple breast cancer clinical settings, with positive early efficacy data reported across TNBC and HER2-positive metastatic breast cancer.

6No material events impacting future operations were disclosed for the period after 31 December 2025 through the report date of 16 March 2026.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Half Year ended 31 December 2025

Metric	Value	Basis	Prior Period
Other Income	$91.9K	GAAP	$22.3K
Finance Income	$160.9K	GAAP	$28.7K
Research and Development Expense	$-5.0M	GAAP	$-4.3M
General and Administrative Expense	$-8.6M	GAAP	$-5.1M
Loss After Income Tax Benefit	$-12.6M	GAAP	$-10.5M
Basic Loss Per Share	$-0.81	GAAP	$-2.46
Diluted Loss Per Share	$-0.81	GAAP	$-2.46

Transaction Details

Material Agreement

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

HALF-YEAR REPORT FOR THE SIX MONTHS ENDED DECEMBER 31, 2025